In the space of a few months, the supply side of point-of-care media reorganized around a small number of platforms, each announcing new electronic health record partnerships and cross-channel extensions. The environments themselves did not change. Who sells access to them did. That changes how the channel has to be planned.
Point of care used to mean a screen in a waiting room or a sponsored page inside a reference tool. It now means authenticated, workflow-embedded media inside the systems clinicians use while making decisions: the record, the order set, the reference lookup, the prescribing moment. The audience is verified by credential rather than inferred from behavior, and the context is clinical rather than editorial. It is the most defensible reach in HCP media, which is why it is also the most contested.
Through 2026 the platforms that already sold programmatic HCP media signed a series of partnerships with the companies that own point-of-care inventory: electronic record environments, clinical reference tools, prescribing-moment messaging, and, most recently, out-of-home screens in clinical settings. Several of those deals were announced within days of one another. Another platform, owned by a large health publisher, reported a step change in its reach through record partnerships and an exclusive arrangement with a workflow vendor.
The practical result is that the same clinical environment can now be reached through more than one seller, at different prices, with different identity methods and different measurement. A brand buying through two platforms may be buying the same screen twice and counting it as incremental reach.
Three planning assumptions no longer hold. The first is that each point-of-care partner offers distinct supply; overlap has to be measured now, not assumed away. The second is that a platform's recommendation of its own newly acquired inventory is a neutral read on where the audience is; it is a sales motion. The third is that the reported match rate and the reported frequency are comparable across sellers; the methods differ, and the definitions of "authenticated" differ with them.
For a named-account launch, the stakes are higher still. When the target is a list of health systems and the clinicians inside them, concentration risk is the whole game. Reaching the same institutions through three overlapping paths inflates cost without adding penetration.
The audit is straightforward and rarely done. List every point-of-care environment the plan proposes to use. For each, identify who owns the inventory, who resells it, and under which contract the brand would be buying. Establish the identity method and what "verified" means in that environment. Measure overlap between paths against the brand's actual target list rather than a generic universe. Score every path on the same criteria: identity, clinical context, measurement, price, and concentration. Then decide which paths the plan needs and which are duplicates.
That map should be built by someone who does not sell any of the paths. The platforms will each produce a version, and each version will favor the inventory the platform now owns.
A supply-path map with owners and contracts, an independent scorecard, an overlap and concentration analysis against the target list, and a recommended set of paths with the rationale attached. From there the negotiation is on the brand's terms, and the point-of-care line in the plan can be defended to finance as reach that is verified, non-duplicative, and priced against alternatives.
The channel is worth the effort. It is the closest healthcare media gets to the prescribing decision. The consolidation did not change that. It changed who needs to be watched.
A fixed-fee audit states the waste in dollars, scores every vendor, and ends in a remediation plan. Twenty minutes to scope it.